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Abstract
Background The optimal treatment strategy for stage I–II
glottic squamous cell carcinoma (SCC) is not well-defined.
This study analyzed treatment results and prognostic fac-
tors.
Patients and methods This is a single-institution retrospec-
tive analysis of 244 patients with T1–2 glottic SCC who
underwent normofractionated radiotherapy (RT) and/or
surgery between 1990 and 2013. The primary endpoint was
relapse-free survival (RFS).
Results Median age was 65 years (range: 36–92 years),
the majority (82%) having stage I disease. Definitive RT
was used in 82% (median dose: 68 Gy, 2 Gy per fraction).
Median follow-up was 59 months. The 5-year RFS rates
were 83 and 75% (p = 0.05) for stage I and 62 and 50%
(p = 0.47) for stage II in the RT and surgery groups, re-
spectively. Multivariate analyses indicate T1 vs. T2 and
RT vs. surgery as independent prognostic factors for RFS,
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with hazard ratios of 0.38 (95% confidence interval, CI:
0.21–0.72) and 0.53 (95% CI: 0.30–0.99), respectively (p <
0.05). The 5-year overall and cause-specific survival rates
in the whole cohort were 92 and 96%, respectively, with
no significant differences between treatment groups. Ante-
rior commissure involvement was neither a prognostic nor
a predictive factor. The incidence of secondary malignan-
cies was not significantly different between patients treated
with and without RT (22 vs. 9% at 10 years, respectively,
p = 0.18).
Conclusion Despite a possible selection bias, our series
demonstrates improved RFS with RT over surgery in stage I
glottic SCC.
Keywords Carcinoma, squamous cell · Laryngeal
neoplasms · Survival · Microsurgery · Laryngectomy
Behandlung früher Glottiskarzinome (T1–2) mit
Strahlentherapie und/oder Operation
Zusammenfassung
Hintergrund Die optimale Behandlungsstrategie für ein
Plattenepithelkarzinom (SCC) der Stimmbänder im Stadi-
um I–II ist nicht gut definiert. In dieser Studie wurden
Behandlungsergebnisse und prognostische Faktoren unter-
sucht.
Patienten und Methoden In dieser retrospektiv unizentri-
schen Studie wurden 244 Patienten mit einem frühen Glot-
tis-SCC (T1–2) zwischen 1990 und 2013 strahlentherapeu-
tisch (RT) und/oder chirurgisch behandelt. Primärer End-
punkt war das rezidivfreie Überleben (RFS).
Ergebnisse Das mediane Alter betrug 65 Jahre (Spanne
36–92). Die Mehrheit (82 %) hatte ein Stadium I. Die me-
diane Tumornachsorge betrug 59 Monate. Von den Patien-
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ten wurden 82% bestrahlt, die Übrigen wurden operiert. Die
mediane RT-Dosis war 68 Gy (2 Gy/Fraktion). Für die ra-
diotherapeutisch und chirurgisch behandelten Gruppen be-
trug das 5-Jahres-RFS 83 bzw. 75 % mit einem Stadium I
(p = 0,05) und 62 bzw. 50 % mit einem Stadium II (p =
0,47). Die multivariaten Analysen zeigen T1- vs. T2-Karzi-
nome und RT vs. Chirurgie als unabhängige prognostische
Faktoren für das RFS, mit Hazard Ratios von jeweils 0,38
(95 %-Konfidenzintervall [KI] 0,21–0,72) und 0,53 (95 %-
KI 0,30–0,99; p < 0,05). Die 5-Jahres-Gesamt- und krank-
heitsspezifische Überlebensrate der ganzen Studienpopula-
tion betrugen 92 % und 96 %, ohne signifikanten Unter-
schied zwischen beiden Therapiestrategien. Die Infiltration
der vorderen Kommissur war weder prognostisch noch prä-
diktiv. Bezüglich der Inzidenz von Zweitmalignomen bei
Patienten mit und ohne RT konnten keine signifikanten Un-
terschiede gefunden werden (22 vs. 9 % nach 10 Jahren;
p = 0,18).
Schlussfolgerung Trotz einer möglichen Stichprobenverzer-
rung zeigen unsere Daten eine im Vergleich zur Chirurgie
bessere RFS bei bestrahltem Stadium-I-Glottis-SCC.
Schlüsselwörter Plattenepithelkarzinom ·
Larynxneoplasien · Überleben · Mikrochirurgie ·
Laryngektomie
About 50–60% of laryngeal squamous cell carcinomas
(SCC) arise from the glottic region [1] and over 80% of
these patients present in an early stage [2]. The larynx
has important roles in production of voice, coordination
of deglutition, and respiration. Therefore, the treatment
aim of laryngeal cancer is not only achievement of max-
imum disease control, but also maintenance of function.
In the absence of large randomized studies providing clear
evidence for the best strategy to treat early stage glottic
SCC, many retrospective studies reported comparable con-
trol rates following radiotherapy (RT) and/or surgery. The
5-year local control rate (LC) following RT ranges from
80 to 95% for T1 and from 61 to 82% for T2 glottic SCC
[3, 4]. The 5-year LC with transoral laser microsurgery is
in the order of 82 to 100% for T1 and 66 to 88% for T2
tumors, which is comparable to the results of open partial
laryngectomy [5–7]. For these early stages, 5-year overall
and disease-free survival rates are in the range of 89–100%
and 60–100%, respectively. In this regard, no significant
differences between surgery and RT are expected [8].
The aim of this retrospective single-institution study was
to assess the oncologic outcome and influencing factors in
treatment of stage I and II (Union for International Can-
cer Control, UICC) glottic SCC with a sufficient follow-up
period.
Patients and methods
Approval of institutional and regional review boards was
obtained. The charts of all patients presented in our Head
and Neck Cancer multidisciplinary tumor board between
1990 and 2013 with histologically proven T1 and T2 inva-
sive purely glottic SCC were reviewed. Staging was revised
according to the 7th edition of the UICC staging system.
Patients with preexisting neoplastic disease were excluded.
Treatment decisions were discussed by board members to
determine the best strategy to preserve laryngeal function
in the absence of a protocol with any predefined selection
criteria. The patients either received definitive RT alone or
underwent surgery.
Radiotherapy was delivered using a two-dimensional
conventional or three-dimensional conformal technique
(2D/3D-RT) in the majority of the cases, which was
followed by an era of intensity-modulated radiotherapy
(IMRT). No bolus was used. Treatment was planned with
6-MV photons. Definitive RT to a total dose of 72 Gy was
delivered in 2 Gy per fraction to the larynx in T2 tumors.
The remaining cases (T1 definitive or T1/2 adjuvant) were
treated to 68 Gy. Target volume encompassed the whole
larynx. Elective neck irradiation encompassing levels II–IV
bilaterally with a dose of 54 Gy was performed for T2
primaries treated with definitive RT. Surgery involved tran-
soral laser microsurgery or open partial laryngectomy.
Adjuvant RT was indicated in cases of close or positive
resection margins.
All patients underwent regular follow-up for at least
5 years after treatment including physical examination with
flexible transnasal endoscopy. There was no standard for
regular imaging studies.
All time-to-event intervals were calculated based on the
date of initial positive biopsy. The follow-up time was not
censored at a given time point. A two-sided log-rank test
was used to evaluate possible prognostic factors such as
age, gender, stage, anterior commissure involvement (ACI),
RT treatment time, and treatment modality for relapse-free
survival (RFS). Variables with p-values 0.05 in univariate
analyses were used to build multivariate models to iden-
tify possible independent risk factors through backwards
elimination. Statistical analyses were performed with JMP
(version 12.1; SAS Institute, Cary, NC, USA).
Results
A total of 244 patients with a median age of 65 years
(range 36–92 years) were diagnosed with stage I–II SCC of
the glottic larynx. The median follow-up was 59 months.
Primary treatments included either definitive RT (82%) or
surgery (18%). Surgery was received by 16 patients, fol-
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Table 1 Patient, disease, and treatment characteristics
Characteristic Number (%)
Whole
cohort
Stage I Stage II
Gender
Male 225 (92) 185 (93) 40 (88)
Female 19 (8) 14 (7) 5 (11)
cT Stage
T1a 153 (63) – –
T1b 46 (19) – –
T2 45 (18) – –
Anterior commissure involvement
Yes 129 (64) 97 (60) 32 (82)
No 73 (36) 66 (40) 7 (18)
Missing information 42 36 6
Primary therapy
RT only 201 (82) 161 (81) 40 (89)
S only 27 (11) 26 (13) 1 (2)
S followed by RT 16 (7) 12 (6) 4 (9)
Type of surgery
Transoral laser micro-
surgery
39 (91) 35 (92) 4 (80)
Open partial laryngectomy 4 (9) 3 (8) 1 (20)
Radiotherapy technique
2D-/3D-RT 183 (85) 151 (88) 32 (73)
IMRT 33 (15) 21 (12) 12 (27)
2D-RT two-dimensional conventional radiotherapy, 3D-RT three-
dimensional conformal radiotherapy, IMRT intensity-modulated
radiotherapy, RT radiotherapy, S surgery
Fig. 1 Relapse-free survival by stage (a) and by primary treatment (b). RT radiotherapy, S surgery; dots represent censored patients lost to
follow-up
lowed by adjuvant RT (37% of the cohort with primary
surgery). The majority (85%) were treated with 2D/3D-RT
rather than IMRT techniques. Median treatment time was
49 days (range 38–56 days) without any statistically signif-
icant impact on outcome parameters. Table 1 summarizes
the patient, disease, and treatment characteristics.
The 5-year overall survival (OS), cause-specific survival
(CSS), and RFS rates for the whole cohort were 92, 96,
and 78%, respectively. Compared to T1, T2 tumors relapsed
more frequently (39 vs. 19%) at 5 years, p < 0.01 (Fig. 1a).
With definitive RT vs. surgery, 5-year RFS rates were 79
and 73%, respectively (p = 0.09; Fig. 1b). Among primary
treatment modalities, OS rates at 2, 5, and 10 years were
98, 91, and 84% with RT; 100, 97, and 90% with surgery,
respectively (p = 0.10).
The 5-year RFS was higher for patients who received RT
as any part of their treatment (either definitive or adjuvant)
than for those who underwent surgery alone (80 vs. 65%;
p < 0.01; Fig. 2a). In patients with T1 primaries, the 5-year
RFS rates with primary RT vs. surgery were 83 and 75%,
respectively (p = 0.05; Fig. 2b). This difference was not
statistically significant in T2 cases (62 vs. 50%; p = 0.47).
The 5-year CSS rates of patients with T1 and T2 were 98
vs. 88%, respectively (p < 0.01; Fig. 3).
For RFS, ACI was neither prognostic nor predictive
when comparing RT to surgery and IMRT to non-IMRT.
Multivariate analysis indicated stage and treatment modal-
ity as independent prognostic variables for RFS with haz-
ard ratios (HR) of 0.38 (95% confidence interval, CI:
0.21–0.72) for T1 vs. T2 and 0.53 (95% CI: 0.30–0.99)
for RT vs. surgery (both p < 0.05). Detailed results of
the univariate and multivariate analyses are provided in
Table 2.
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Fig. 2 Relapse-free survival with and without any radiotherapy (a) and in T1 tumors by primary treatment (b). Dots represent censored patients
lost to follow-up; RT radiotherapy, S surgery
Fig. 3 Cause-specific survival by stage. Dots represent censored pa-
tients lost to follow-up
We observed a median time to relapse of 25 months.
The majority of relapses occurred locally. The 2- and 5-year
RFS rates after salvage treatment were 75 and 65%, respec-
tively. The patterns of relapse and subsequent treatments are
shown in Table 3.
A second primary cancer developed in 30 patients
(12%), of which 10 were diagnosed as head and neck
cancer (HNC), all being SCC, and 22 as non-HNC (two
patients had both). Localizations are provided in the supple-
mentary table. The incidence rates of second malignancies
showed an increase in patients with vs. without definitive
or adjuvant RT, but without statistical significance (Fig. 4).
Among patients who did not experience any relapse;
1 needed a permanent feeding tube and 2 had tracheotomy
due to laryngeal stenosis at last follow-up; 2 further patients
had both. No patient suffered from aspiration or underwent
a functional laryngectomy. The laryngectomy rates among
survivors at 2, 5, and 10 years were 5, 8, and 14% in stage I;
17, 28, and 32% in stage II, respectively (p < 0.01). All la-
ryngectomies were performed as salvage surgery and not
due to functional deterioration.
Discussion
The main objective of this study was to report the out-
come of stage I–II glottic SCC patients treated by our
multidisciplinary HNC team and to identify possible fac-
tors which may influence the outcome. Through the analy-
ses, two prognostic factors emerged. First, stage as a well-
known prognostic factor [9]; and second, treatment modal-
ity. To our knowledge, there are no prospective randomized
trials providing a proper comparison of RT and surgery of
early glottic SCC in terms of oncologic or functional out-
come. In 1990, a multicenter randomized controlled trial
was published [10] which compared the outcomes of open
surgery, RT, or chemoradiotherapy in early glottic SCC. The
available English abstract draws concerns about trial design
and methodology. Another prospective randomized study
comparing laser microsurgery vs. normofractionated RT for
the treatment of T1a glottic SCC was published by Aaltonen
et al. [11], where the primary endpoint was voice quality.
The trial was stopped after 10 years due to low accrual,
with only 20% of the planned sample size reached. Recur-
rence rates were comparable, but repeated-measure analy-
ses demonstrated statistically significant improvements in
voice quality with RT in assessments of breathiness, asthe-
nia, glottal closure (expert-rated), and impact on everyday
life (patient-rated).
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Table 2 Univariate and
multivariate analyses for
relapse-free survival
Univariate analyses Multivariate model after back-
wards elimination
Variable HR (95% CI) p-value HR (95% CI) p-value
Age (>65/65 years) 1.07 (0.57–1.98) 0.84 – –
Gender (female/male) 0.19 (0.01–0.90) 0.03 – –
Stage (I/II) 0.34 (0.18–0.67) 0.003 0.38 (0.21–0.72) 0.003
ACI (yes/no) 0.86 (0.45–1.68) 0.64 – –
Primary treatment (RT/S) 0.71 (0.32–1.77) 0.43 0.53 (0.30–0.99) 0.049
RT time (days; >49/49) 1.08 (0.55–2.03) 0.81 – –
ACI anterior commissure involvement, CI confidence interval, HR hazard ratio, RT radiotherapy, S surgery
Table 3 Patterns of relapse and treatments
Failure at first relapse Stage I Stage II
Total number of relapses 40 (20%) 16 (36%)
Local 85% 75%
Isolated neck nodes 5% 6%
Local + neck nodes 10% 13%
Distant only – 6%
Treatment of first relapse
Salvage RT 20% –
Salvage S 45% 50%
Salvage S + RT 30% 25%
Systemic chemotherapy 5% 13%
Palliative RT – 6%
Best supportive care – 6%
RT radiotherapy, S surgery
Fig. 4 Incidence of secondary malignancies with and without radio-
therapy as part of the primary treatment. Dots represent censored pa-
tients lost to follow-up; RT radiotherapy, S surgery
In the absence of prospective randomized trials, a va-
riety of meta-analyses and systematic reviews were pub-
lished comparing RT to surgery with various methodologies
and findings. In a meta-analysis including 27 studies com-
paring RT to laser microsurgery, no significant difference
in oncologic outcome, but a trend toward improved voice
quality following RT was reported [12]. Similarly, another
systematic review and meta-analysis included 19 studies
with T1a glottic larynx cancer showed no significant differ-
ences in LC, OS, disease-specific survival, or voice quality
following RT or surgery [13]. A recent extensive system-
atic review reported similar oncologic outcomes for stage I
patients who received RT or underwent surgery with or
without laser [14]. Hai-Lan et al. showed in a meta-analy-
sis that laser surgery delivered significantly better OS and
laryngeal preservation than RT in T1 primaries, without,
however, significant differences in LC in T1 tumors, which
puts a question mark on the quality of the analysis concern-
ing patient selection bias [15]. Similarly, a recent Surveil-
lance, Epidemiology, and End Results (SEER) data analysis
showed superior OS with surgery over RT without report-
ing any LC or disease-specific outcome rates [16]. A re-
cent systematic review of LC outcomes explicitly for T2
glottic tumors treated with either RT or laser surgery didn’t
show any difference in 5-year LC between the two treatment
groups [17]. The last update of the Cochrane review on this
topic showed no significant differences in 5-year OS or dis-
ease-free survival in stage I and II glottic SCC with RT or
surgery [8]. The authors emphasized the lack of consistent
and high-level evidence needed to draw any conclusions. In
our cohort, RFS was higher in T1 patients treated with RT
than those who underwent surgery. However, our cohort is
subject to selection bias due to its retrospective nature. First
of all, there is a clear imbalance between the numbers of
patients treated with primary RT and surgery. A concerning
number (around one third) of the surgically treated patients
underwent adjuvant RT instead of re-resection. Addition-
ally, our recurrence rates are higher than those reported in
the literature. This may be explained by our previous in-
stitutional policy apparently favoring RT over surgery in
early-stage laryngeal cancer, not only as the first treatment
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option but also in cases of close and positive resection mar-
gins, which underwent a major change few years ago.
Altered fractionation with shorter overall treatment times
corresponds to better tumor control and survival benefit
in HNC [18–23]. During the last decade, two prospec-
tive randomized trials answered this fractionation question
specifically in early-stage glottic SCC [24, 25], favoring
hypofractionation (2.25 Gy). On the other hand, contrary
to what was expected, Radiation Therapy Oncology Group
(RTOG) 9512 showed increased toxicity and futility with
hyperfractionation in T2 glottic larynx cancer [26]. Using
accelerated RT, the results of the DAHANCA 6 trial showed
a significant improvement in locoregional control of glottic
SCC with a HR of 0.60 (CI: 0.41–0.89) with a median fol-
low-up of 14.5 years. There were no significant differences
in long-term toxicity among accelerated RT and normofrac-
tionation [27]. In our cohort, this observation could not be
reproduced, probably due to the fact that the majority of the
patients were treated once daily and RT time was normally
distributed, with a prominent accumulation around the me-
dian value of 49 days. The outliers were patients whose
treatments were either arbitrarily accelerated or delayed for
various reasons.
In our series, all patients in stage II received elective
nodal irradiation to the levels II–IV bilaterally. However, re-
cently published large series showed the futility of this prac-
tice [3, 27]. Some retrospective studies demonstrated that
ACI is a poor prognostic factor for RT outcomes [28–32],
but these results are not consistent in the literature [7]. Some
authors pointed out the possible underdosage of tumors with
ACI close to the skin caused by the air–tissue interface
[33]. In our series, we did not observe a prognostic impact
of ACI, regardless of technique. However, patients treated
with IMRT represented only 15% of our whole cohort.
While IMRT is known to be used for its general benefits
in terms of decreasing toxicity in the treatment of laryn-
geal cancer [34], the still widely used approach for early-
stage glottis SCC is to treat the whole larynx as a compart-
ment. This approach is based on the traditional conventional
field design, which was established in an era where image
guidance in RT was poor. Another reason was the laryn-
geal displacement due to swallowing during RT, which was
later reported not to be a serious concern [35, 36]. This
approach has two major consequences. First, it exposes an
unnecessary volume of healthy tissue to a high dose (i. e.,
overtreatment), which may increase the risk of functional
loss through inflammation and fibrosis, at the same time
depleting the reserves for future re-irradiation, if required.
Second, the carotid arteries are exposed to a high dose,
which increases the incidence of stenosis and cerebrovascu-
lar events [37, 38]. Chera et al. [39] overcame this problem
through modified target volumes and IMRT. With a newer
technique developed by the Rotterdam group, it is possi-
ble to apply 58.08 Gy in 16 fractions just to the involved
vocal cord, with a significant dose reduction in the vicin-
ity [40]. Recently, this group reported the clinical results
of a prospective study with the primary endpoint of voice
quality [41]. With a median follow-up of 30 months, 2-year
LC and OS were 100 and 90%, respectively, without any
grade ≥3 toxicity. When compared with a historical cohort
treated to the whole larynx (66/2 Gy), single vocal cord ir-
radiation yielded less grade ≥2 acute toxicity (17 vs. 66%,
p < 0.01) and lower Voice Handicap Index scores in all fol-
low-up visits performed in regular short intervals until the
18th month (p < 0.01).
High second malignancy rates in HNC patients is a major
problem. With each passing year, about 3% of the treated
early-stage head and neck SCC (HNSCC) patients are ex-
pected to develop a second primary malignancy [42, 43].
In the SEER database analysis (n = 27,985) published by
Rusthoven et al. [44], a reduced incidence of secondary
HNC was observed in patients treated with vs. without RT
(HR 0.71, p < 0.01). The difference was still significant in
the laryngeal subsite on multivariate analysis. The authors
suggested that RT had a preventive effect on transforma-
tion of the subclinical malignant foci. This observation is
consistent with results of another analysis of 987 laryngeal
cancer patients treated between 1967 and 2004, where RT
was not found to increase the risk of second primary tumor
incidence [45]. In our study, 12% of patients developed
a second primary cancer with a non-significant increase
in patients treated definitively or adjuvantly with RT (RT
22%; surgery only 9%). However, our median follow-up
of 5 years is not enough to observe any meaningful differ-
ence or exclude the long-term possibility of an increased
incidence of second malignancies in any of the treatment
groups. Furthermore, the hypothesis regarding ablation of
the premalignant foci with RT may be invalid or less promi-
nent in the IMRT era, and if still present, this effect might be
limited in the treatment of early glottic SCC, where elective
nodal irradiation is often omitted.
Our present study has limitations due to its retrospective
nature, which predisposes the results to potential bias. It
represents two imbalanced treatment groups, therefore lim-
iting the robustness of comparisons (RT vs. surgery). Ad-
ditionally, due to its retrospective nature, we were not able
to report on toxicities, smoking and alcohol consumption
status.
Conclusion
Our series demonstrate a better RFS with RT compared
surgery for stage I glottic SCC with a given risk of possible
selection bias. The lack of level 1 evidence comparing these
K
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treatment modalities compels careful interpretation of our
results.
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